Abstract 15436: High-Sensitivity C-Reactive Protein Predicts New-Onset Heart Failure in Patients Treated With Moderate-Intensity Statin for Primary Prevention
Background: The inflammatory biomarker high-sensitivity C-reactive protein (hsCRP) is known to be associated with the progression and worsening of heart failure (HF). We evaluated the clinical significance of hsCRP on the development of new onset HF in patients (pts) taking moderate-intensity statin for primary prevention.
Methods: Pts without HF at baseline were enrolled and divided into 4 quartiles according to hsCRP levels. HF was defined as N-terminal pro-B-type natriuretic peptide (NT-proBNP) > 400 pg/ml. New-onset HF as primary endpoint and other cardiovascular events as secondary endpoints were evaluated up to 9 years.
Results: Compared to the lowest quartile (< 0.46 mg/L, n=1224), the highest quartile (>1.86 mg/L, n=1194) of hsCRP was associated with a higher incidence of new-onset HF [OR= 2.28, (95% CI 1.63-3.20), P <0.001]. Even after proportional hazard cox-regression adjusted by age, gender, cardiovascular comorbidities including arrhythmia, hypertension, diabetes, chronic kidney disease, laboratory parameters and medications including types of statins, there was a weaker but still significant relationship between higher levels of hsCRP and the development of new-onset HF [HR= 1.74, (95% CI 1.23-2.46), P =0.002, figure].
Conclusions: In our study, hsCRP levels remaining high even after moderate-intensity statin treatment significantly predicted the development of new-onset HF during long-term follow-up. Risk stratification according to the level of hsCRP may help identify pts who need additional attention for future deterioration of cardiac function.
Author Disclosures: Y. Park: None. S. Rha: None. B. Choi: None. J. Byun: None. S. Choi: None. J. Kang: None. W. Kim: None. J. Choi: None. E. Park: None. S. Park: None. S. Lee: None. H. Li: None. J. Na: None. C. Choi: None. J. Kim: None. H. Lim: None. E. Kim: None. C. Park: None. H. Seo: None. D. Oh: None.
- © 2016 by American Heart Association, Inc.